Every approved medication, from a common antibiotic to a breakthrough cancer therapy, followed the same fundamental path to market. That path is the drug development pipeline, a structured process of testing that moves a potential new treatment from laboratory discovery through progressively larger and more rigorous human studies before it reaches patients through commercial sale. Understanding this pipeline is foundational knowledge for anyone working in clinical research, because it provides the context for why each phase of a clinical trial is designed the way it is, and why the regulatory framework governing clinical trials is structured the way it is.
The Pipeline at a Glance
Drug development follows a defined sequence: preclinical research, IND application, Phase I through Phase III clinical trials, regulatory submission and review, marketing approval, and post-marketing Phase IV surveillance. Each stage builds on the evidence generated in the previous one, with the intent of establishing whether a new compound is safe and effective for its intended use in the intended patient population. The entire process, from initial discovery to first approval, typically takes 10 to 15 years and costs hundreds of millions to over a billion dollars, with estimates ranging from $868 million to $1.2 billion per approved drug[1] and the majority of costs concentrated in the late-stage clinical phase.
Preclinical Research: Before the First Human
Laboratory testing on cells and animals to assess basic safety, mechanism of action, pharmacokinetics, and potential efficacy before any human exposure is considered.
Before a drug candidate ever enters a human body, it must demonstrate sufficient promise in laboratory testing to justify the risk. Preclinical research involves in vitro (cell culture) and in vivo (animal) studies designed to characterize the compound's pharmacology, how it works, how it is absorbed and metabolized, how it is eliminated, and its toxicology, at what doses and in what formulations does it cause harm.
The goal of preclinical testing is not to prove that a drug is safe for humans. It is to gather enough evidence to make a reasonable scientific case that the risk of initial human exposure is justified and that the proposed human dose range is appropriate. Preclinical data also provides the foundational pharmacokinetic models that guide dose selection in Phase I.
Many compounds fail at this stage. A drug that looks promising in cell culture may show unacceptable toxicity in animals. A compound that works in a mouse model may fail to show the same mechanism in a primate model that more closely approximates human biology. Preclinical failure is essential and appropriate — it prevents compounds that would fail in humans from ever reaching human trials.
The IND Application: Permission to Begin Human Testing
Before the first human participant can receive an investigational drug in the United States, the sponsor must file an Investigational New Drug (IND) application with the FDA under 21 CFR Part 312. The IND is not an approval: it is a notice to the FDA with sufficient data to support the safety of proceeding to human studies. The FDA has 30 days to review the IND and either allow the investigation to proceed or place it on clinical hold.[4]
The IND contains: the preclinical data supporting proposed first-in-human dosing; the protocol(s) for the initial clinical investigation; information about the investigational product's chemistry, manufacturing, and quality; the qualifications of the investigators; and the procedures for monitoring participant safety. For CRCs, the IND is the document that creates the regulatory framework within which their site operates, all study activities, SAE reporting, and protocol changes flow through the IND.
Phase I: First-in-Human Safety
First administration of the investigational product to humans. Primary objectives are determining the maximum tolerated dose, characterizing pharmacokinetics and pharmacodynamics, and identifying dose-limiting toxicities.
Phase I trials are the smallest and most tightly monitored trials in the development program. For most oncology drugs, Phase I participants are patients who have exhausted other treatment options. They enroll with the understanding that therapeutic benefit is uncertain and that safety evaluation is the primary objective. For most non-oncology drugs, Phase I participants are healthy volunteers who receive the drug with no expectation of personal therapeutic benefit.
The typical Phase I design is dose escalation: starting doses are well below the preclinical toxicity threshold, and small cohorts of participants receive escalating doses until either a maximum tolerated dose (MTD) is defined or a pre-specified maximum dose is reached without dose-limiting toxicity. Pharmacokinetic sampling — measuring blood concentrations of the drug at defined time intervals — is intensive in Phase I, which is why Phase I units often require multiple blood draws per participant per visit.
Phase I also commonly includes pharmacodynamic studies (measuring the drug's effect on biological markers), food effect studies (comparing absorption with and without food), and drug-drug interaction studies (evaluating how the drug behaves in the presence of commonly co-administered medications). Together, Phase I generates the data package needed to design a meaningful efficacy study in Phase II.
Phase II: Does It Work?
Testing in the intended patient population to assess whether the drug produces the expected biological effect, refine the optimal dose, and generate preliminary safety data in patients rather than healthy volunteers.
Phase II is where the drug first faces patients with the target disease or condition. The primary objectives shift from maximum tolerated dose to efficacy signal: does the drug produce a measurable clinical effect in the intended population at the doses identified as safe in Phase I? Phase II trials also continue safety monitoring in a larger, more heterogeneous population than Phase I.
Phase II trials are often divided into Phase IIa (proof of concept — does this drug work in humans with this disease?) and Phase IIb (dose finding, at what dose does the efficacy signal optimize?). The evidence generated in Phase II shapes the design of the pivotal Phase III program, including the primary endpoint selection, the comparator arm, the patient population definition, and the sample size calculations.
Many drugs fail in Phase II, either because they fail to show a meaningful efficacy signal or because safety issues emerge in the patient population that were not apparent in healthy volunteers. Phase II failure, while costly, is far less costly than Phase III failure, which is why sponsors invest heavily in Phase II signal-detection before committing to the large-scale Phase III investment.
Phase III: The Pivotal Evidence
Large-scale randomized controlled trials designed to provide the definitive evidence of safety and efficacy required for marketing approval. Typically conducted across multiple sites and countries simultaneously.
Phase III trials are the pivotal trials that generate the primary evidence submitted to the FDA in a marketing application. They are large, randomized, typically double-blind, and usually controlled against either placebo or the current standard of care. Their design must be sufficiently powered to detect a clinically meaningful difference in the primary endpoint with statistical significance.
For most conditions, the FDA requires at least two adequate and well-controlled Phase III trials demonstrating substantial evidence of effectiveness before approving a new drug.[2] This two-trial requirement reflects the FDA's standard for the replication of evidence — a single positive trial could be a chance finding; two independent positive trials provide much stronger evidence of a genuine treatment effect.
Phase III trials are where most CRCs spend the majority of their careers. The scale of Phase III — hundreds of sites, thousands of participants, years of enrollment and follow-up — means that the site-level work of consent, visit conduct, data entry, and adverse event reporting is performed by thousands of CRCs simultaneously across the global trial network.
NDA/BLA Submission and FDA Review
When Phase III is complete, the sponsor compiles the full clinical development data package into a New Drug Application (NDA) for small-molecule drugs, or a Biologics License Application (BLA) for biological products, and submits it to the FDA under 21 CFR Parts 314 and 601, respectively. The submission includes all clinical trial data, preclinical data, chemistry/manufacturing information, proposed labeling, and the statistical analysis package.
The FDA aims to complete standard drug application reviews within 10 months, and within 6 months for Priority Review applications (granted for drugs addressing serious conditions with unmet medical need).[2] During review, the FDA evaluates whether the evidence demonstrates substantial evidence of effectiveness, whether the safety profile is acceptable relative to the condition being treated, and whether the proposed labeling accurately represents the benefit-risk profile.
If the FDA approves, the drug receives marketing authorization for the indication(s) studied. If the FDA issues a Complete Response Letter (CRL), it requests additional data or changes before approval can be granted. Approval does not mean the drug has been proven safe and effective for all possible uses: it means the evidence submitted supports its safety and effectiveness for the specific indication, population, and dosing described in the approved labeling.
Phase IV: Post-Marketing Surveillance
Post-marketing studies and surveillance tracking safety and effectiveness in the broader patient population, including populations not well represented in Phase III trials and rare adverse events that only emerge with widespread use.
Approval is not the end of the evidence generation process: it is the beginning of a new phase. Phase IV encompasses all post-marketing clinical activities: required post-marketing studies the FDA mandated as a condition of approval, voluntary studies the sponsor conducts to expand the drug's label or support commercial positioning, pharmacovigilance programs tracking adverse events in the approved population, and real-world evidence studies using healthcare data to assess long-term outcomes.
Phase IV is where rare but serious adverse events often first emerge. Phase III trials, despite their size, may not be large enough or long enough to detect adverse events that occur at rates of 1 in 10,000 or that require years of exposure to manifest. The FDA's MedWatch system and the sponsor's pharmacovigilance program continuously monitor post-marketing safety data, and drugs can be withdrawn, relabeled, or have new safety warnings added at any point post-approval based on emerging evidence.
Timeline and Attrition: Why Drug Development Is Hard
The average time from initial discovery to first approval is approximately 10 to 15 years. Industry research has historically shown that approximately 10 percent of drugs entering Phase I clinical trials ultimately receive FDA approval, with the likelihood of approval from Phase I remaining consistently low across therapeutic areas.[3] The attrition is highest between Phase II and Phase III, where the gap between early efficacy signals and definitive evidence in larger populations is most likely to reveal that a drug does not perform as hoped.
This attrition rate explains why pharmaceutical development is so expensive and why individual clinical trials are conducted with such rigorous attention to protocol compliance, data quality, and participant protection. A Phase III trial that fails due to a data quality problem, rather than a genuine lack of drug efficacy — represents a catastrophic and avoidable loss of years of work and enormous resources. The CRC's role in maintaining protocol compliance and generating credible data is not peripheral to this process. It is central to it.
Where CRCs Fit in the Pipeline
CRCs work in Phase I through Phase IV, with the greatest concentration of CRC roles in Phase II and Phase III. Phase I units, particularly in oncology — employ specialized Phase I coordinators who develop expertise in pharmacokinetic sampling procedures, dose-escalation protocols, and close participant safety monitoring. Phase II coordinators often work in smaller, single-center studies with intensive per-patient procedures. Phase III CRCs manage larger participant panels across longer study durations, with the primary focus on visit window compliance, data quality across a large CRF, and long-term participant retention.
Phase IV CRCs work in post-marketing registry studies, required post-marketing trials, and observational studies, often with less intensive per-visit procedures but with different challenges around long-term follow-up and large participant panels in settings that may be less tightly resourced than pivotal Phase III sites.
Understanding where your specific study falls in this pipeline, what question it is trying to answer, what evidence it is generating, and why the specific procedures and endpoints it requires are designed the way they are — makes you a materially better coordinator. Protocol mastery starts with understanding the development context, not just the visit schedule.
Sources
- Ciociola AA et al. How drugs are developed and approved by the FDA: current process and future directions. Am J Gastroenterol. 2014;109(5):620–3. Cost estimates $868M–$1.2B per approved drug.
- U.S. Food & Drug Administration. Development & Approval Process (Drugs). FDA.gov. Confirms standard review goal (10 months), Priority Review (6 months), and two-trial standard for substantial evidence of effectiveness.
- Takebe T et al. The current status of drug discovery and development as originated in United States academia. Clin Transl Sci. 2018;11(6):597–606. Phase I to approval likelihood of approximately 10%.
- U.S. Food & Drug Administration. The Drug Development Process. FDA.gov. Overview of preclinical, IND, Phase I–IV, and post-market surveillance stages.